Avalanche shares continute to fall off a cliff as company ditches eye drug trial

It's back to the preclinical drawing board for the investigational wet AMD drug. 

By Sy Mukherjee • Aug. 14, 2015

AbbVie, Genentech to seek US approval of potential blockbuster leukemia med

AbbVie/Roche's venetoclax is being tested in chronic lymphocytic leukemia (CLL) patients with a gene mutation that slashes survival rates. 

By Sy Mukherjee • Aug. 12, 2015

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Clovis & Genentech team up to test out a promising lung cancer combo

The companies want to see if the dual therapy using an EGRF inhibitor and a PD-L1 blocker can be more effective in treating NSCLC patients. 

By Sy Mukherjee • Aug. 12, 2015

Hat trick: AstraZeneca cuts its 3rd cancer drug deal in a week

AZ is now officially on a cancer drug roll with this latest deal with Inovio.

By Randy Lilleston • Aug. 10, 2015

CNS-focused US cannabis patch company raises $42M in IPO

Pennsylvania's Zynerba Pharma plans to move into clinical trials with cannabinoid-laced transdermal patches for treatment of epilepsy and other CNS disorders.

By Nicole Gray • Aug. 6, 2015

A rare case: Young woman with Duchenne's waiting for a cure

The odds of a girl having the disease are one in 50 million. 

By Nicole Gray • Aug. 4, 2015

All-in? AstraZeneca soldiers forward with psoriasis hopeful despite suicide link

And despite the fact that these very concerns led Amgen to back out of its co-development arrangement for the drug with AZ.

By Nicole Gray • Aug. 3, 2015

Finally: Merck Ebola vax triumphs in phase III trial, overcoming logistical nightmare

The investigational vaccine, which the WHO is calling "exciting" and "promising," was apparently 100% effective in protecting patients. And the trial's success is a testament to teamwork and coordination.

By Sy Mukherjee • July 31, 2015

Sanofi's LixiLan aces a late-stage trial, setting up diabetes showdown with Novo

The study combined the investigational compound with Sanofi's flagship insulin product Lantus.

By Nicole Gray • July 30, 2015

Why Pfizer is abandoning its OTC Lipitor program

The fault, in this case, may actually lie with patient compliance. 

By Nicole Gray • July 30, 2015

Want a better placebo effect? Stick to needles over pills

A study published in the Annals of Internal Medicine show that the manner in which a placebo is administered can determine how it works. 

By Nicole Gray • July 29, 2015

EU upholds massive drug ban over alleged CRO data manipulation

Several drug makers approached the European Medicines Agency (EMA) to appeal the suspension—but they were unsuccessful. 

By Nicole Gray • July 28, 2015

2nd gen radiotracers and Alzheimer's diagnosis in the age of early-intervention trials

The AAIC has identified earlier, more precise diagnosis as an important factor in developing drugs to treat early-stage Alzheimer’s. Navidea Biopharmaceuticals is on the forefront of this effort with its next-generation radiotracer, NAV4694.

By Nicole Gray • July 24, 2015

European regulators just announced a massive overhaul of pediatric waivers

As part of a larger effort to increase the number of clinical trials involving children, the European Medicines Agency (EMA) is revoking or modifying most pediatric waivers.

By Nicole Gray • July 24, 2015

BMS and Exelixis make headway against Novartis in kidney cancer

But the Swiss pharma giant is still defending its cancer med Afinitor.

By Nicole Gray • July 23, 2015

A tough setback for AZ as major eye cancer hopeful flunks phase III

At one point, selumetinib was hailed as a potential blockbuster based on strong mid-stage survival data. 

By Nicole Gray • July 23, 2015

Roche renews commitment to R&D of two AD drugs

As the Alzheimer's research community bets bigger on the beta-amyloid theory, Roche has re-committed to two antibody drugs that target amyloid protein.

By Nicole Gray • July 23, 2015

A mixed bag: Biogen's & Lilly's hotly anticipated Alzheimer's data are inconclusive

Both companies' shares fell in early morning trading as the results proved far murkier than many had hoped.

By Sy Mukherjee • July 22, 2015

Promising stem-cell clinical trial results for rare lung disease

In the trial, reserachers evaluated the effect of genetically enhanced stem cell therapy on lung blood pressure levels in pulmonary arterial hypertension (PAH). 

By Nicole Gray • July 22, 2015

NEJM: Early HIV therapy delays AIDS-related events & death

In a clinical study, 1.8% of HIV-positive patients who received immediate treatment experienced a serious health outcome over a three-year period, compared with 4.1% of patients who delayed treatment.

By Nicole Gray • July 21, 2015

Researchers are about to launch the largest AIDS treatment trial ever

Researchers at UCSF are planning a 100-patient trial that determines whether very early treatment of HIV infection, followed by an interruption, can lead to a functional cure after promise in a French AIDS patient. 

By Nicole Gray • July 20, 2015

Bristol-Myers' rock star Opdivo continues to roll, this time in kidney cancer

An ongoing trial was stopped early after Opdivo proved more effective than everolimus in providing a survival advantage. 

By Nicole Gray • July 20, 2015

Amgen's leukemia drug excels in phase II for new indication

Amgen is going after a new indication for Blincyto (blinatumomab) and has reached some success.  

By Nicole Gray • July 20, 2015

Why some new drugs are truly earning the 'innovative' label

Many so-called innovative drug approvals rely on an established mode of action. So what makes a drug truly innovative?  

By Nicole Gray • July 16, 2015

ASCO scorecard upgrades rating for Lilly's Alimta

Alimta (pemetrexed) fell short on an initial scorecard, but its score improved when ratings were focused on a more specific form of lung cancer.

By Nicole Gray • July 16, 2015